Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 1/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SQOR | Q9Y6N5 | 3/20 | 0.38 |
| ▸ | KDM1A | O60341 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ACP1 | P24666 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4492030 | 0.88 | CYP1A1 (0.40) | CYP1A1CYP1B1CYP11B1CYP11B2NPC1 | |
| SCHEMBL4479136 | 0.85 | CYP11B2 (0.45) | CYP11B1CYP11B2NPC1ALDH1A1RAB9A | |
| SCHEMBL4491173 | 0.81 | ALDH1A1 (0.44) | NPC1ALDH1A1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL4481278 | 0.79 | CYP11B2 (0.45) | CYP11B1CYP11B2NPC1ALDH1A1RAB9A | |
| SCHEMBL3929098 | 0.75 | ESR1 (0.55) | PIM1 | |
| SCHEMBL4482483 | 0.74 | NPC1 (0.44) | NPC1ALDH1A1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL4475462 | 0.74 | KDM4E (0.53) | NPC1ALDH1A1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL4490844 | 0.73 | NPC1 (0.43) | NPC1ALDH1A1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL4480387 | 0.73 | CYP11B1 (0.45) | CYP11B1CYP11B2NPC1ALDH1A1RAB9A | |
| SCHEMBL27638483 | 0.71 | ESR1 (0.45) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632845-B2 | 2-(p-oxyphenyl)-6-oxyquinolines, e.g., 2-(3-Fluoro-4-hydroxyphenyl)-4-phenylquinolin-6-ol; inflammatory bowel disease; Crohn's disease; anticarcinogenic agents; anticholesterol agents; antilipemic agents; cardiovascular diorders; osteoporosis; A lzheimer's disease; fertility; antiarthritic agents | WYETH (US) | 2009-12-15 | — | — | US | disclosed |
| US-7632845-B2 | 2-(p-oxyphenyl)-6-oxyquinolines, e.g., 2-(3-Fluoro-4-hydroxyphenyl)-4-phenylquinolin-6-ol; inflammatory bowel disease; Crohn's disease; anticarcinogenic agents; anticholesterol agents; antilipemic agents; cardiovascular diorders; osteoporosis; A lzheimer's disease; fertility; antiarthritic agents | WYETH (US) | 2009-12-15 | — | — | US | disclosed |
| US-7632845-B2 | 2-(p-oxyphenyl)-6-oxyquinolines, e.g., 2-(3-Fluoro-4-hydroxyphenyl)-4-phenylquinolin-6-ol; inflammatory bowel disease; Crohn's disease; anticarcinogenic agents; anticholesterol agents; antilipemic agents; cardiovascular diorders; osteoporosis; A lzheimer's disease; fertility; antiarthritic agents | WYETH (US) | 2009-12-15 | — | — | US | disclosed |
| US-20060217399-A1 | Phenyl quinolines and their use as estrogenic agents | WYETH (US) | 2006-09-28 | — | — | US | disclosed |
| US-7084276-B2 | Phenyl quinolines and their use as estrogenic agents | WYETH (US) | 2006-08-01 | — | — | US | disclosed |
| EP-1628961-A1 | PHENYL QUINOLINES AND THEIR USE AS ESTROGEN RECEPTOR MODULATORS | Wyeth (US) | 2006-03-01 | — | — | EP | disclosed |
| US-20050009784-A1 | Phenyl quinolines and their use as estrogenic agents | WYETH | 2005-01-13 | — | — | US | disclosed |
| WO-2004103973-A1 | PHENYL QUINOLINES AND THEIR USE AS ESTROGEN RECEPTOR MODULATORS | WYETH (US) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009784-A1 | Phenyl quinolines and their use as estrogenic agents | ESR1, GPER1, ESR2 | CYP1A1 23/4885CYP1B1 62/4885CYP11B1 120/4885 |
| US-20060217399-A1 | Phenyl quinolines and their use as estrogenic agents | ESR1, GPER1, ESR2 | CYP1A1 23/4885CYP1B1 62/4885CYP11B1 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.